Immuno-Oncology in vitro assays
Therapeutic Area
Recent therapeutic advances in immuno oncology include the clinical use of check-point-inhibitors, bispecific antibodies and cellular therapeutics. Our human relevant in vitro assays are designed to evaluate single and combinatorial therapies across all therapeutic modalities. These models enable the assessment of complex therapeutics that engage multiple cellular targets within the tumour microenvironment. Example T cell assays include CD8 cytotoxicity, CD8 exhaustion, while our NK assays assess ADCC and MHC independent cytotoxicity.
Key Assays
Example of key assays designed to test novel immuno-oncology therapies such as check-point-inhibitors, bispecifics, ADC’s, cellular therapies and nutraceuticals
Frequently Asked Questions
Do you offer 3D tumour models to study immune cell mediated tumour killing?
Yes, we provide 2D and 3D in vitro tumor models to study direct or immune-mediated tumor killing for immuno-oncology research. Our 2D and 3D models are used to test efficacy of mono and combination therapeutics.
What tumour types can you work with in your assays?
We work with a wide range of tumor types, including lung, breast, colorectal, and melanoma. Our immune-mediated tumor killing assays use real-time imaging and key inflammatory cytokines such as IFNγ to assess therapeutic effects. We have a panel of clinically relevant NucLight Red labelled tumour cell lines for screening and can include new tumour types, on request.
What type of therapeutics can be tested in your assays?
Our in vitro immune oncology assays are designed to test therapeutics that target both immune cells and tumour cells including small molecules, monoclonal antibodies, checkpoint inhibitors, cellular therapies and antibody-drug conjugates.
What Our Partners say about Nexus
Drug Discovery Tool
Find the right immune assay for your therapeutic area, modality and target using our interactive Drug Discovery Tool.
